Rational Pharmacotherapy in Cardiology

Advanced search

Antihypertensive Drug Utilization in Two Districts of Northern Cyprus

Full Text:


Aim. Since the irrational use of medicine increases the risk of morbidity and mortality in hypertension, this study was aimed to evaluate antihypertensive pharmacotherapy at two districts of Northern Cyprus (NC).

Material and methods. A total of 148 prescriptions including antihypertensive drugs (n=181) were obtained by the aid of five pharmacists between November 2017 August 2018 and evaluated regarding the antihypertensive drug choices and good prescribing principles. The prescribed antihypertensive agents were classified according to the Anatomical Therapeutic Chemical Classification System (ATC) 2, 3 and 5 and the prescriptions were evaluated regarding the availability of format information.

Results. The mean of antihypertensive agents per prescription was 1.2±0.6. According to the ATC-3 subclassification, beta-blockers (22.1%), angiotensin receptor blockers (ARBs) (22.1%), calcium channel blockers (20.4%), angiotensin converting enzyme inhibitor (ACE) inhibitors (17.7%), diuretics (13.8%) and anti-adrenergic drugs (3.9%) were prescribed. According to the ATC-5 subclassification, the most common prescribed antihypertensives were metoprolol (16.6%), amlodipine (16.0%), furosemide (8.8%), captopril (7.7%) and losartan (6.6%). There were no significant relation between the prescribed antihypertensive agents and gender and the physicians serving either in governmental or private hospitals. There were shortcomings in the prescriptions such as age, diagnosis and drug information which were crucial for the chosen of an appropriate antihypertensive agent.

Conclusion. This first pharmacoepidemiological study about antihypertensive drug utilization in NC indicates the imperfections of physicians in terms of prescribing antihypertensive agents according to the guidelines and writing a “legible and good” prescription that contains full information. These findings underline necessity of educational interventions for physicians to disseminate rational use of medicine (RUM) in the NC.

About the Authors

M. Tamirci
European University of Lefke, Faculty of Pharmacy Lefke

Mevhibe Tamirci – PhD (pharmacology), Department of Pharmacology, Faculty of Pharmacy

Northern Cyprus, TR-10 Mersin, Turkey

R. Demirdamar
European University of Lefke, Faculty of Pharmacy Lefke

Rümeysa Demirdamar ‒ PhD (pharmacology), Professor, Department of Pharmacology, Faculty of Pharmacy

Northern Cyprus, TR-10 Mersin, Turkey


1. Vasan R.S., Beiser A., Seshadri S., et al. Residual lifetime risk for developing hypertension in middleaged women and Men. JAMA. 2002;287:1003-10. DOI:10.1001/jama.287.8.1003.

2. Benowitz N.L. Antihypertensive agents. In: Katzung B.G., Masters S.B., Trevor A.J., eds. Basic and Clinical Pharmacology, 12th ed. New York: McGraw Hill; 2012. pp.169-90.

3. Kannel W.B., Gordon T. Evaluation of cardiovascular risk in the elderly: the Framington study. Bulletin of the New York Academy of Medicine. 1978;54(6):573-91.

4. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. DOI:10.1093/eurheartj/eht151.

5. Guideline for the diagnosis and management of hypertension in adults 2016. National heart foundation of Australia [cited by Jul 02, 2019]. Available from:

6. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324. DOI:10.1161/HYP. 0000000000000066.

7. NICE guideline. Hypertension in adults: diagnosis and management [cited by May 28, 2019]. Available from:

8. WHO. The rational use of drugs: report of the conference of experts. Nairobi: World Health Organization; 1985.

9. Rizzo J.A., Simons W.R. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1997;19(6):1446-57. DOI:10.1016/S01492918(97)80018-5.

10. Fulhaber H.D., Luft F.C. Treatment of high blood pressurein Germany. Am J Hypertens.1998:11:7503. DOI:10.1016/s0895-7061(98)00068-5.

11. State Planning Organization. Population and indicators [cited by Jul 02, 2019]. Available from:

12. Jassim Al Khaja K.A., Sequeira R.P., Mathur V.S. Rational Pharmacotherapy of hypertension in the elderly: analysis of the choice and dosage drugs. J Clin Phar Therap. 2001;26:33-42. DOI:10.1111/j.1365-2710.2001.00324.x.

13. Akici A., Kalaça S., Uğurlu U., Toklu H.Z., Oktay Ş. Antihypertensive drug utilization at health centers in a district of Istanbul. Pharm World Sci. 2007;29:116-21. DOI:10.1007/s11096-007-9103-5.

14. Obreli Neto P.R., Nobili A., de Lyra D.P. Jr, et al. Incidence and predictors of adverse drug reactions caused by drug-drug interactions in elderly outpatients. A prospective cohort study. J Pharm Pharm Sci. 2012;15(2):332-43.

15. Bakare O.Q., Akinyinka M.R., Goodman O., et al. Antihypertensive use, prescription patterns and cost of medications in a Teaching Hospital in Lagos, Nigeria. Niger J Clin Pract. 2016;19:668-72. DOI:10.4103/1119-3077.188709.

16. Yürüyen G., Toprak İ.D., Toprak Z., et al. Choice of treatment based on Turkish hypertension consensus repost: Do we fellow the recommendations? Turk Kardiyol Dern Ars. 2018;46(1):25-31. DOI:10.5543/tkda.2017.86344.

17. Sequeira R.P., Al Khaja K.A., Damanhori A.H.H., Mathur V.S. Prescribing pattern on antihypertensive drugs by family physicians and general practitioners in the primary care setting in Bahrain. J Eval Clin Pract. 2002;8(4):407-14. DOI:10.1046/j.1365-2753.2002.00370.x.

18. Gasse C., Stieber J., Döring A., Keil U., Hense H.W. Population trends in antihypertensive drug use: results from the MONICA Augsburg Project 1984 to 1995. J Clin Epidemiol. 1999;144:726-32. DOI:10.1016/S0895-4356(99)00035-9.

19. Selmanovic K., Zec S.L., Vanis N., et al. Utilisation analysis of antihypertensive drugs in Bosna and Herzegovina for the time-period 2013-2015. Mater Sociomed. 2016;28:116-20.

20. Zanchetti A., Ruilope L.M. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens. 2002;20:2099-110.

21. Secondary prevention of non-communicable diseases in lowand middle-income countries through community-based and health service interventions. Report of the Cambridge Meeting. World Health Organization and Wellcome Trust, 2001 [cited by Jul 02, 2019]. Available from:

22. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28.

23. Dahlöf B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. DOI:10.1016/S0140-6736(05)67185-1.

24. Hutton B., Yazdi F., Hersi M., et al. Drug safety and effectiveness network report: A systemic review with network meta-analyses and economic evaluation comparing therapies for hypertension in nondiabetic patients. Ottawa: University of Ottowa, 2014 [cited by Jul 02, 2019]. Available from:


For citations:

Tamirci M., Demirdamar R. Antihypertensive Drug Utilization in Two Districts of Northern Cyprus. Rational Pharmacotherapy in Cardiology. 2019;15(4):467-477.

Views: 671

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)